Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
March 11 2024 - 8:00AM
Daxor Corporation (Nasdaq: DXR), the global leader in blood
volume measurement technology today announces the expansion of
blood volume analysis (BVA) in three new hospitals through new
analyzer purchases, and the utilization of Daxor’s ezBVA Lab
service. These new acquisitions further fuel BVA sales growth and
underscore its clinical relevance.
New client and services wins include:
- BVA analyzer purchase at a 735-bed
non-profit, tertiary, research and academic medical center located
in northern New Jersey.
- Daxor’s ezBVA Lab service extended
to a regional academic medical center, Level I adult trauma center
in Ohio.
- Daxor’s ezBVA Lab service extended
to an academic, integrated health system located in South
Carolina.
“Our sales and marketing teams have kicked off
the new calendar year with great momentum, and these new account
openings in the past two weeks are further evidence of the more
rapid uptake of our diagnostic solutions,” said Michael Feldschuh,
Daxor’s CEO and President. “We remain focused on commercialization
- broadening our reach with new analyzer sales, while driving
increased utilization within our current customer base, supported
by our expanding ezBVA Lab service. The continued growth of our
client base paves the way for further adoption of our
next-generation systems set to launch in the near term.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Apr 2024 to May 2024
Daxor (NASDAQ:DXR)
Historical Stock Chart
From May 2023 to May 2024